NovoCure's cancer therapy effective in late-stage study
(Reuters) - NovoCure Ltd said its lead cancer therapy improved survival rate in brain cancer patients in combination with Avastin in a late-stage study, sending its shares up 23 percent in extended trading.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Avastin | Brain | Brain Cancers | Cancer | Cancer & Oncology | Cancer Therapy | Health | Neurology | Study